Stanford phd candidate Calvin schmidt posts about investing opportunities in synthetic biology. Available for consulting on potential investments in this area.

Calvin Schmidt Synthetic Biology Index: June Update

Performance overview
Value at beginning of month: $95,584.27
Value at end of month: $101,388.15
Month over month change: +6.07%
Total CAGR: +2.80%
 
Related indices, monthly change
NASDAQ: -2.62%
IVV (iShares Core S&P 500): -0.92%
IBB (iShares NASDAQ Biotechnology Index): +4.83%
MXI (iShares Global Materials): -1.01%
VEGI (iShares MSCI Global Agriculture Producers): -2.18%
ICLN (iShares Clean Energy): -1.72%
 
Individual performances

Gains by several of the index’s largest companies (Genscript, Intrexon, Codexis, Horizon) brought the index to its best month yet. Amyris shares continued to fall, even as the company announced a new partnership to build a new refinery in Australia.
 
Changes made to index
 
None
 
Allocation as of June 30, 2017

Calvin Schmidt Synthetic Biology Index: July Update

Calvin Schmidt Synthetic Biology Index: May Update